NAFDAC Reg. No. B4-5603 Estupefaciente
Pero sobre el medicamento, Nepafenac: uses, dosage and brands worldwide
Generado automáticamente a partir del registro NAFDAC, QUIÉN alerta y los datos de la comunidad a partir de hoy. Este no es un consejo médico. Siga siempre a su médico o farmacéutico.
Lo que dice el prospecto oficial. Si te lo recetó un médico, sigue la receta. Si el prospecto de tu caja es distinto, manda el de tu caja.
ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).
Sterile ophthalmic suspension 0.3%: 1.7 mL in a 4 mL bottle and 3 mL in a 4 mL bottle. Sterile ophthalmic suspension 0.3%: 3 mL in a 4 mL bottle. ( 3 )
The safety and effectiveness of ILEVRO ® 0.3% in pediatric patients below the age of 10 years have not been established.
No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Increased bleeding time due to interference with thrombocyte aggregation ( 5.1 ) Delayed healing ( 5.2 ) Corneal effects including keratitis ( 5.3 ) 5.1 Increased Bleeding Time With some NSAIDs including ILEVRO ® 0.3%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. It is recommended that ILEVRO ® 0.3% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. …
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 1-833-4HARROW or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . …
8.1 Pregnancy Teratogenic Effects. Pregnancy Category C: Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. …
Tómala en cuanto te acuerdes, salvo que falte poco para la siguiente. En ese caso, sáltate la olvidada. Nunca tomes dos dosis a la vez para compensar. Revisa tu prospecto, porque algunos medicamentos son distintos.
Label for nepafenac, the active ingredient registered with NAFDAC.
Add the expiry date on your pack for a full Trust Score.
Nepafenac Ophthalmic Suspension contains Nepafenac (0.1%), as suspension/drops, according to its NAFDAC registration record.
Yes. Nepafenac Ophthalmic Suspension is listed on the NAFDAC register under registration number B4-5603, and its registration is active as of 18 November 2026.
No WHO falsified or substandard medical product alert currently matches Nepafenac Ophthalmic Suspension in our automatically synced alert list.
Run a free authenticity scan with the NAFDAC number B4-5603, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.
Follow your prescription or the leaflet in your pack. The official label says: One drop of ILEVRO ® 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. ( 2 ) 2.1 Recommended Dosing One drop of ILEVRO ® 0.3% should be applied to the affected …
ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ). (Summarised from the official U.S. FDA label for nepafenac. Always follow your doctor or pharmacist.)
Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.